AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19846001 — intervention group
Group type: COMPARATOR
Intervention: Control group at PEEP 5 cm H(2)O
Number of subjects: 30
Study 19846001 — intervention group
Group type: COMPARATOR
Intervention: Control group at PEEP 10 cm H(2)O
Number of subjects: 30
Study 19846001 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP levels 0 to 10 cm H(2)O
Number of subjects: 30
Study 19846001 — intervention group
Group type: COMPARATOR
Intervention: Control group at all PEEP levels
Number of subjects: 30
Study 16452919 — intervention group
Group type: EXPERIMENTAL
Intervention: Dealcoholised red wine (DRW)
Number of subjects: 45
Study 16452919 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine (RW)
Number of subjects: 45
Study 16452919 — intervention group
Group type: COMPARATOR
Intervention: Water (Control)
Number of subjects: 45
Study 15079128 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (31 patients)
Number of subjects: 110
Study 15079128 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (34 patients)
Number of subjects: 110
Study 15079128 — intervention group
Group type: COMPARATOR
Intervention: Surgery (control group, 45 patients)
Number of subjects: 110
Study 15079128 — intervention group
Group type: COMPARATOR
Intervention: Surgery (control group)
Number of subjects: 110
Study 15079128 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative treatment (overall)
Number of subjects: 110
Study 15079128 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy (overall)
Number of subjects: 110
Study 11463561 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (cisplatin 100 mg/m² on day 1 and etoposide 120 mg/m² on days 1-3 for six cycles)
Number of subjects: 66
Study 11463561 — intervention group
Group type: COMPARATOR
Intervention: Control group (surgery alone)
Number of subjects: 66
Study 12526358 — intervention group
Group type: EXPERIMENTAL
Intervention: rIFN alpha‐2b 1 x 10(6)U per day, i.m., for three days
Number of subjects: 146
Study 12526358 — intervention group
Group type: COMPARATOR
Intervention: Traditional combined therapy with a predominance of balanced solution
Number of subjects: 146
Study 8070497 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg of the ACE inhibitor perindoprilat
Number of subjects: 10
Study 8070497 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 10
Study 2738728 — intervention group
Group type: EXPERIMENTAL
Intervention: Transparent adhesive dressing (TAD), n = 6
Number of subjects: 13
Study 2738728 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control), n = 7
Number of subjects: 13
Study 2738728 — intervention group
Group type: EXPERIMENTAL
Intervention: TAD, n = 6
Number of subjects: 13
Study 29420063 — intervention group
Group type: EXPERIMENTAL
Intervention: Random spice isolates producing enterotoxin at levels of 4 to 16 ng/mL
Number of subjects: 247
Study 29420063 — intervention group
Group type: EXPERIMENTAL
Intervention: D95°C levels of spores from four randomly selected spice isolates
Number of subjects: 247
Study 29420063 — intervention group
Group type: EXPERIMENTAL
Intervention: One spice isolate with D95°C
Number of subjects: 247
Study 29420063 — intervention group
Group type: EXPERIMENTAL
Intervention: Five of the 43 isolates
Number of subjects: 247
Study 26139307 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab (50 mg subcutaneously every 4 weeks)
Number of subjects: 198
Study 26139307 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study 23915113 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta 1b (IFNB)
Number of subjects: 19
Study 23915113 — intervention group
Group type: COMPARATOR
Intervention: Natalizumab (NTZ)
Number of subjects: 19
Study 21668284 — intervention group
Group type: EXPERIMENTAL
Intervention: Articaine HCl
Number of subjects: 162
Study 21668284 — intervention group
Group type: EXPERIMENTAL
Intervention: Prilocaine HCl
Number of subjects: 162
Study 21668284 — intervention group
Group type: COMPARATOR
Intervention: Maxillary infiltration
Number of subjects: 162
Study 21668284 — intervention group
Group type: COMPARATOR
Intervention: Mandibular nerve block
Number of subjects: 162
Study 19578678 — intervention group
Group type: COMPARATOR
Intervention: Zero minutes of nicotine abstinence
Number of subjects: 201
Study 19578678 — intervention group
Group type: COMPARATOR
Intervention: 30 minutes of nicotine abstinence
Number of subjects: 201
Study 19578678 — intervention group
Group type: COMPARATOR
Intervention: 60 minutes of nicotine abstinence
Number of subjects: 201
Study 16913264 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine, 5 mg
Number of subjects: 722
Study 16913264 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine, 180 mg
Number of subjects: 722
Study 16913264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 722
Study 15578470 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 21
Study 15578470 — intervention group
Group type: COMPARATOR
Intervention: Control (Saline)
Number of subjects: 21
Study 11453957 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment, average daily dose 2.4 IU (SD 0.86)
Number of subjects: 12
Study 11453957 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 12
Study 9209724 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing treatment
Number of subjects: 35
Study 9209724 — intervention group
Group type: COMPARATOR
Intervention: Successful tapering off medication
Number of subjects: 35
Study 9113123 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron
Number of subjects: 259
Study 9113123 — intervention group
Group type: COMPARATOR
Intervention: Antiemetic cocktail (metoclopramide, dexamethasone, lorazepam)
Number of subjects: 259
Study 9113123 — intervention group
Group type: COMPARATOR
Intervention: Tropisetron plus placebo
Number of subjects: 259
Study 9113123 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron plus dexamethasone
Number of subjects: 259
Study 3042317 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofibrate (1.5 g/day)
Number of subjects: 70
Study 3042317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 31679120 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg Oxycodone Tamper-Resistant Tablet (OTR)
Number of subjects: 38
Study 31679120 — intervention group
Group type: COMPARATOR
Intervention: 40 mg OXYCONTIN® (OXY)
Number of subjects: 38
Study 30942008 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical moxibustion, 2 times a week for 12 weeks
Number of subjects: 116
Study 30942008 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (Control group)
Number of subjects: 116
Study 30942008 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after treatment (Observation group)
Number of subjects: 116
Study 28268074 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated zoster vaccine (ZVIN), 4-dose regimen (∼30 days between doses)
Number of subjects: 80
Study 26536057 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Group Psychotherapy (GPT)
Number of subjects: 419
Study 26536057 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Clinical Management (CM)
Number of subjects: 419
Study 26536057 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 419
Study 26536057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 419
Study 26536057 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate with GPT
Number of subjects: 419
Study 26536057 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate with CM
Number of subjects: 419
Study 23216089 — intervention group
Group type: EXPERIMENTAL
Intervention: New research coding strategy designed to introduce the virtual channel effect
Number of subjects: 9
Study 23216089 — intervention group
Group type: COMPARATOR
Intervention: MP3(000™)
Number of subjects: 9
Study 17012141 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral beta‐1,3/1,6‐glucan 700 mg (Group 1)
Number of subjects: 21
Study 17012141 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral beta‐1,3/1,6‐glucan 1400 mg (Group 2)
Number of subjects: 21
Study 17012141 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 3)
Number of subjects: 21
Study 12709037 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive multiple-infusion episode-based protocol
Number of subjects: 0
Study 12709037 — intervention group
Group type: COMPARATOR
Intervention: Standard alternate-day prophylaxis
Number of subjects: 0
Study 12709037 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized escalating dose and frequency of routine replacement infusions of factor concentrate
Number of subjects: 0
Study 10427667 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Doppler measurements of the fetal ductus arteriosus
Number of subjects: 418
Study 7572679 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/day)
Number of subjects: 6595
Study 7572679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6595
Study 1675048 — intervention group
Group type: EXPERIMENTAL
Intervention: Apraclonidine hydrochloride
Number of subjects: 20
Study 1675048 — intervention group
Group type: COMPARATOR
Intervention: Apraclonidine and timolol (combined)
Number of subjects: 20
Study 1675048 — intervention group
Group type: COMPARATOR
Intervention: Apraclonidine alone or timolol alone
Number of subjects: 20
Study 7015795 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (75-450 mg daily)
Number of subjects: 24
Study 7015795 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (75-450 mg daily) + Hydrochlorothiazide (50-100 mg daily)
Number of subjects: 24
Study 7015795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 7015795 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Hydrochlorothiazide (50-100 mg daily)
Number of subjects: 24
Study 7015795 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 24
Study 31774483 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive aids
Number of subjects: 144
Study 31774483 — intervention group
Group type: COMPARATOR
Intervention: No cognitive aids (Control)
Number of subjects: 144
Study 29973172 — intervention group
Group type: EXPERIMENTAL
Intervention: Newborn Behavioral Observation (NBO) method during home visits from 3 weeks to 3 months postpartum
Number of subjects: 2800
Study 29973172 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (Control group)
Number of subjects: 2800
Study 29973172 — intervention group
Group type: EXPERIMENTAL
Intervention: NBO method
Number of subjects: 2800
Study 28486709 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT; lozenge, patch, both)
Number of subjects: 1122
Study 28486709 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion (alone or with nicotine lozenge)
Number of subjects: 1122
Study 28486709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1122
Study 25600258 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous nerve stimulation with biofeedback capability
Number of subjects: 0
Study 25600258 — intervention group
Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 0
Study 24025626 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobalamin supplementation (400 μg hydroxycobalamin intramuscularly)
Number of subjects: 79
Study 24025626 — intervention group
Group type: COMPARATOR
Intervention: Sham injection (placebo)
Number of subjects: 79
Study 20717875 — intervention group
Group type: EXPERIMENTAL
Intervention: HMC05 (500 mg tablets, 3 times daily for 4 weeks)
Number of subjects: 14
Study 20717875 — intervention group
Group type: COMPARATOR
Intervention: Placebo (500 mg tablets, 3 times daily for 4 weeks)
Number of subjects: 14
Study 20717875 — intervention group
Group type: EXPERIMENTAL
Intervention: HMC05
Number of subjects: 14
Study 20717875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 18670888 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (socio-educational workshops)
Number of subjects: 404
Study 18670888 — intervention group
Group type: COMPARATOR
Intervention: Control group (delayed intervention)
Number of subjects: 404
Study 15705087 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic tamsulosin initiated 2 weeks before implantation and continued until IPSS returned to normal
Number of subjects: 130
Study 15705087 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic alpha-blocker
Number of subjects: 130
Study 15705087 — intervention group
Group type: EXPERIMENTAL
Intervention: 103Pd isotope
Number of subjects: 130
Study 15705087 — intervention group
Group type: EXPERIMENTAL
Intervention: 125I isotope
Number of subjects: 130
Study 15705087 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic alpha-blockers
Number of subjects: 130
Study 15705087 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental radiotherapy and/or androgen deprivation therapy
Number of subjects: 130
Study 15705087 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum IPSS after implantation
Number of subjects: 130
Study 12851876 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil 10‐mg therapy for 48 weeks
Number of subjects: 694
Study 10778338 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-stretch compression bandage
Number of subjects: 43
Study 10778338 — intervention group
Group type: COMPARATOR
Intervention: Short-stretch compression bandage
Number of subjects: 43
Study 8740244 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 10 mg for 1 month, 20 mg for 1 month, 40 mg for 4 months
Number of subjects: 50
Study 8740244 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 1880344 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diclofenac
Number of subjects: 37
Study 1880344 — intervention group
Group type: COMPARATOR
Intervention: Topical timolol
Number of subjects: 37
Study 6761123 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow release oxprenolol 160 mg twice daily
Number of subjects: 4000
Study 6761123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4000
Study 6761123 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow release oxprenolol
Number of subjects: 4000
Study 30863632 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose IQP-AE-103
Number of subjects: 108
Study 30863632 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose IQP-AE-103
Number of subjects: 108
Study 30863632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 30863632 — intervention group
Group type: EXPERIMENTAL
Intervention: IQP-AE-103
Number of subjects: 108
Study 28209040 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD community integrated management system
Number of subjects: 460
Study 28209040 — intervention group
Group type: COMPARATOR
Intervention: Essential diagnosis and treatment services
Number of subjects: 460
Study 26022508 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) - bolus dose of 0.5 µg·kg‐1 within 10 min, maintenance dose of 0.5 µg·kg‐1·h‐1
Number of subjects: 99
Study 26022508 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate (ETO) - bolus dose of 0.3 mg·kg‐1 without maintenance dose
Number of subjects: 99
Study 26022508 — intervention group
Group type: COMPARATOR
Intervention: Routine anesthetics (Control Group)
Number of subjects: 99
Study 24316712 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate implant placement
Number of subjects: 15
Study 24316712 — intervention group
Group type: COMPARATOR
Intervention: Delayed implant placement
Number of subjects: 15
Study 22284296 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous forces (150 g) applied with 0.017 × 0.025-in Beta III Titanium cantilever springs, reactivated every 2 weeks
Number of subjects: 32
Study 22284296 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous forces (150 g) applied with 0.017 × 0.025-in Beta III Titanium cantilever springs, reactivated every 3 weeks
Number of subjects: 32
Study 22284296 — intervention group
Group type: COMPARATOR
Intervention: Intermittent forces with a pause of 3 days before each reactivation
Number of subjects: 32
Study 22284296 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous forces (150 g)
Number of subjects: 32
Study 22284296 — intervention group
Group type: COMPARATOR
Intervention: Intermittent forces
Number of subjects: 32
Study 19573637 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular pertussis-containing quadrivalent pre-school booster (Td(5)ap-IPV; Repevax)
Number of subjects: 0
Study 19573637 — intervention group
Group type: COMPARATOR
Intervention: Whole-cell pertussis (DTwP//Hib+oral poliomyelitis vaccine [OPV]) combination vaccine
Number of subjects: 0
Study 19573637 — intervention group
Group type: COMPARATOR
Intervention: Acellular pertussis, diphtheria, tetanus, inactivated poliovirus, Haemophilus influenzae type b (DT(5)aP‐IPV‐Hib; Pediacel)
Number of subjects: 0
Study 17877658 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs) including fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram
Number of subjects: 0
Study 17877658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15191447 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective cervical cerclage
Number of subjects: 135
Study 15191447 — intervention group
Group type: COMPARATOR
Intervention: Cervical surveillance program
Number of subjects: 135
Study 12376442 — intervention group
Group type: EXPERIMENTAL
Intervention: Curtains impregnated with lambdacyhalothrin
Number of subjects: 2913
Study 12376442 — intervention group
Group type: COMPARATOR
Intervention: Curtains without insecticide or no curtains (control group)
Number of subjects: 2913
Study 9872701 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaiser Permanente (KP) model of consultation
Number of subjects: 0
Study 9872701 — intervention group
Group type: EXPERIMENTAL
Intervention: State model of consultation
Number of subjects: 0
Study 9872701 — intervention group
Group type: COMPARATOR
Intervention: Control model
Number of subjects: 0
Study 9872701 — intervention group
Group type: EXPERIMENTAL
Intervention: State model of consultation (high-risk group)
Number of subjects: 0
Study 9872701 — intervention group
Group type: EXPERIMENTAL
Intervention: KP model of consultation (high-risk group)
Number of subjects: 0
Study 9872701 — intervention group
Group type: EXPERIMENTAL
Intervention: State model of consultation (low-risk group)
Number of subjects: 0
Study 9872701 — intervention group
Group type: EXPERIMENTAL
Intervention: KP model of consultation (low-risk group)
Number of subjects: 0
Study 7644049 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg oral sumatriptan
Number of subjects: 667
Study 7644049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 667
Study 10313312 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic radiotherapy following mastectomy
Number of subjects: 0
Study 10313312 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 72237 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral disopyramide (100 mg four times daily)
Number of subjects: 0
Study 72237 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 0
Study 31374589 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG) with optimal medical therapy (OMT)
Number of subjects: 0
Study 31374589 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG) with surgical ventricular reconstruction (SVR)
Number of subjects: 0
Study 31374589 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy (OMT) alone
Number of subjects: 0
Study 31374589 — intervention group
Group type: COMPARATOR
Intervention: Surgical ventricular reconstruction (SVR) alone
Number of subjects: 0
Study 28537418 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulation of the thoracolumbar junction (Experimental Group, n=23)
Number of subjects: 46
Study 28537418 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure (Control Group, n=23)
Number of subjects: 46
Study 25662415 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric care
Number of subjects: 400
Study 25662415 — intervention group
Group type: COMPARATOR
Intervention: Orthopaedic care
Number of subjects: 400
Study 23388527 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO therapy (3 times per week for 6 months)
Number of subjects: 93
Study 21767407 — intervention group
Group type: EXPERIMENTAL
Intervention: etoricoxib 90 mg
Number of subjects: 387
Study 21767407 — intervention group
Group type: EXPERIMENTAL
Intervention: etoricoxib 120 mg
Number of subjects: 387
Study 21767407 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen 1000 mg
Number of subjects: 387
Study 21767407 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 387
Study 19567491 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital treatment of OSA using auto-adjusting positive airway pressure along with standard treatment of ADHF
Number of subjects: 46
Study 19567491 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment for ADHF
Number of subjects: 46
Study 17012419 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate (90 mg single dose)
Number of subjects: 50
Study 17012419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 15268624 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly humanised anti-IL-6R monoclonal antibody (MRA)
Number of subjects: 100
Study 15268624 — intervention group
Group type: EXPERIMENTAL
Intervention: Every-4-weeks regimen of MRA
Number of subjects: 100
Study 15268624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 11139984 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole
Number of subjects: 0
Study 11139984 — intervention group
Group type: COMPARATOR
Intervention: L-dopa
Number of subjects: 0
Study 9235470 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive mechanical ventilation
Number of subjects: 2300
Study 9235470 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent noninvasive ventilation
Number of subjects: 2300
Study 1604411 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral administration of CN-100 at a dose of 150 mg
Number of subjects: 12